- Home
- ACRS vs DDI Comparison
ACRS vs DDI Comparison
Compare ACRS & DDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | DDI |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | South Korea |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.9M | 559.0M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACRS | DDI |
|---|---|---|
| Price | $5.56 | $11.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $10.20 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.9M | 116.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | $6.65 |
| Revenue Next Year | $4.24 | $2.64 |
| P/E Ratio | ★ N/A | $4.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $8.10 |
| 52 Week High | $5.69 | $12.35 |
Technical Indicators
Market Signals| Indicator | ACRS | DDI |
|---|---|---|
| Relative Strength Index (RSI) | 71.90 | 51.34 |
| Support Level | $4.13 | $11.25 |
| Resistance Level | N/A | $12.30 |
| Average True Range (ATR) | 0.29 | 0.26 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 84.43 | 40.00 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About DDI DoubleDown Interactive Co. Ltd. American Depository Shares
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States, while it also has its presence in Canada, Germany, United Kingdom, and International-Other. The games offered by the company are: Doubledown Casion, Doubledown Fortknox, and Doubledown Classic Slots.